Organon & Co. (NYSE:OGN) Receives Average Recommendation of “Moderate Buy” from Analysts

Organon & Co. (NYSE:OGN) has earned an average recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $18.00.

Several research firms have recently commented on OGN. Morgan Stanley reduced their price objective on Organon & Co. from $15.00 to $10.00 and set an “equal weight” rating for the company in a research note on Monday, May 5th. BNP Paribas upgraded Organon & Co. to a “strong-buy” rating in a research report on Thursday, May 22nd. Piper Sandler decreased their price objective on Organon & Co. from $24.00 to $18.00 and set an “overweight” rating on the stock in a research note on Thursday, May 15th. Finally, Evercore ISI cut Organon & Co. from an “outperform” rating to an “inline” rating in a research report on Friday, May 2nd.

Insider Buying and Selling at Organon & Co.

In other news, CEO Kevin Ali bought 34,000 shares of Organon & Co. stock in a transaction dated Monday, May 5th. The shares were acquired at an average price of $8.80 per share, with a total value of $299,200.00. Following the completion of the purchase, the chief executive officer now owns 282,731 shares in the company, valued at $2,488,032.80. The trade was a 13.67% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Daniel Karp bought 3,500 shares of the stock in a transaction dated Tuesday, May 6th. The stock was purchased at an average price of $8.24 per share, with a total value of $28,840.00. Following the acquisition, the vice president now directly owns 46,669 shares in the company, valued at approximately $384,552.56. The trade was a 8.11% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 102,345 shares of company stock worth $902,430 over the last 90 days. 1.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Organon & Co.

A number of large investors have recently bought and sold shares of the business. Millstone Evans Group LLC bought a new position in Organon & Co. in the 4th quarter worth about $29,000. Ransom Advisory Ltd bought a new position in Organon & Co. in the first quarter worth approximately $32,000. Larson Financial Group LLC increased its holdings in Organon & Co. by 345.4% during the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock worth $33,000 after purchasing an additional 1,734 shares during the period. Riverview Trust Co raised its position in Organon & Co. by 117.7% during the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock valued at $36,000 after purchasing an additional 1,292 shares in the last quarter. Finally, GeoWealth Management LLC bought a new stake in Organon & Co. during the 4th quarter valued at $41,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Shares of NYSE OGN opened at $9.82 on Thursday. The firm’s 50-day moving average price is $9.86 and its 200-day moving average price is $13.16. Organon & Co. has a 52-week low of $8.01 and a 52-week high of $23.10. The company has a market cap of $2.55 billion, a PE ratio of 3.41, a PEG ratio of 1.02 and a beta of 0.59. The company has a quick ratio of 1.15, a current ratio of 1.67 and a debt-to-equity ratio of 16.49.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, May 1st. The company reported $1.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.13. The business had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.53 billion. Organon & Co. had a net margin of 11.92% and a return on equity of 227.43%. The company’s quarterly revenue was down 6.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.22 EPS. As a group, analysts anticipate that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 12th. Investors of record on Monday, May 12th were issued a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.81%. The ex-dividend date was Monday, May 12th. Organon & Co.’s dividend payout ratio (DPR) is presently 2.78%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.